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Abstract
Nuclear medicine has become a key part of molecular imaging. In the present review article, we focus on the
transbilayer phospholipids as exquisite targets for radiolabelled probes in molecular imaging. Asymmetry of
phospholipid distribution is a characteristic of mammalian cell membranes. Phosphatidylcholine and
sphyngomyelin cholinophospholipids are primarily located within the external leaflet of the cell membrane.
Phosphatidylserine and phosphatidylethanolamine aminophospholipids, and also phosphatidylinositol are primarily
located within the internal leaflet of the cell membrane. New radiolabelled tracers have been designed in
preclinical and clinical research for PET-CT and SPECT-CT molecular imaging of transbilayer phospholipids.
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Introduction
In this beginning of the twenty-first century, personalized
molecular medicine is the objective of molecular diagno-
sis, molecular imaging, and molecular therapy [1,2].
Molecular imaging (MI) includes a number of morpholo-
gical imaging techniques (i.e. ultrasound, computed
tomography and magnetic resonance imaging), and opti-
cal imaging techniques (i.e. bioluminescence and fluores-
cence imaging) [3,4]. In addition, nuclear medicine with
radiolabelled probes has become a key part of MI, espe-
cially with
18F-fluorodeoxyglucose (
18F-FDG) metabolic
imaging [5]. New radiolabelled tracers have been
designed for positron emission tomography-computed
tomography (PET-CT) and single-photon emission com-
puted tomography-computed tomography (SPECT-CT)
molecular imaging [6]. In this review article, we focus on
the transbilayer phospholipids as exquisite targets for
radiolabelled probes in molecular imaging.
Molecular imaging
There is no universally accepted definition of molecular
imaging [5,7]. In 2000, the Society of Molecular Imaging
http://www.molecularimaging.org/ defined molecular
imaging as: ‘the characterization and measurement of
biological processes in living animals at the cellular and
molecular level’. In 2005, the European Society for Mole-
cular Imaging http://www.e-smi.eu formulated a
definition of molecular imaging as: ‘the characterisation
of the dynamics of the molecular processes in the living
organisms in vivo. In vivo molecular imaging is a science
combining molecular biology, cellular biology and phy-
siology with imaging in living subjects’. In 2006, the Fed-
eration of Asian Societies for Molecular Imaging
(FASMI: http://fasmi.org/) defined molecular imaging as:
‘ the characterization and measurement of biological pro-
cesses in living animals at the cellular and molecular
level by means of non-invasive (or minimally invasive)
imaging’. In 2007, the Society of Nuclear Medicine Mole-
cular Imaging Center of Excellence http://interactive.
snm.org/ definitions task force approved this definition
of molecular imaging as: ‘the visualization, characteriza-
tion, and measurement of biological processes at the
molecular and cellular levels in humans and other living
systems’ [8]. A MI probe is a molecule used in molecular
imaging to deliver a tracer to a specific organ or tissue. A
probe typically consists of a ligand containing or linked
to a signalling label. The label provides the signal (i.e.
electromagnetic wave, light and radiation) that can be
picked up by a detector, and the ligand carries the tracer
to the site of interest [9]. A MI target used in molecular
imaging is a molecule or structure in the body to which
binds a probe delivered to a specific organ or tissue. The
target may be a peptide, or a glucide, or a lipid; in many
cases, the target is a protein [10,11]. Molecular imaging
may be a single disease/gene or a general disease/biologic
function control point for targeting [12].
Molecular imaging with transbilayer phospholipid tar-
gets may be performed with radiolabelled probes such
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domain I or beta 2 glycoprotein I, radiolabelled duramy-
cin, radiolabelled hypericin, radiolabelled lactadherin,
radiolabelled choline or fluorocholine, radiolabelled dia-
cylglycerols, radiolabelled sphyngomyelin for visualiza-
tion, characterization and measurement of key biological
functions (i.e. apoptosis, necrosis, thrombosis, vascula-
ture endothelium, choline metabolism, myocardial and
neuronal phosphoinositide turnover) or for assessing
specific diseases (i.e. cancers, immune diseases, inflam-
matory diseases, infectious diseases, cardiac diseases and
neurological diseases).
Membrane bilayer
The membrane bilayer is composed of 40% lipids and
glycolipids, and 60% integral proteins and glycoproteins
[13]. The lipids in the membrane bilayer are composed
of phospholipids (75% to 88%), glycosphyngolipids (2%
to 5%) and cholesterol (10% to 20%) [13]. The phospho-
lipids include phosphatidylcholine (45% to 55%), phos-
phatidylethanolamine (15% to 25%), phosphatidylinositol
(10% to 15%), phosphatidylserine (2% to 10%), phospha-
tidic acid (1% to 2%), sphyngomyelin (5% to 10%) and
cardiolipin (2% to 5%). Liposomes are artificial lipid vesi-
cles encapsulating drugs (e.g. chemotherapy drugs, anti-
biotics, fungicides), enzymes, biological material (e.g.
antigens, antibodies) and tracers (e.g. radiolabelled pro-
ducts, contrast agents) [14]. Liposomes are nanoparticles
with a diameter < 100 nm characterised by the composi-
tion of lipids, the number of membrane bilayers, and the
surface charges [7]. The material encapsulated is either
dissolved in an aqueous phase or in a lipid phase. Radio-
active phospholipid liposomes have been designed for
molecular imaging [15].
Phospholipid bilayer
In 1972, Singer and Nicolson developed the fluid mosaic
model to explain the composition of the cell membrane
bilayer with randomly oriented globular proteins and
lipids [16]. According to this thermodynamic model, the
phospholipid membrane bilayer is composed of hydro-
philic heads and hydrophobic tails. The polar hydrophilic
heads are in contact with water (see Figure 1). Recent
refinements of the Singer-Nicolson mosaic model suggest
a structured dynamic organisation of the membrane
bilayer with genetically predefined non-randomly
oriented globular proteins into the lipid matrix [17,18].
In mammalians, the asymmetry of phospholipid distribu-
tion is a characteristic of cell membranes (see Figure 2).
Phosphatidylcholine (PC) and sphyngomyelin (SM) choli-
nophospholipids are primarily located in the extracellular
membrane. Phosphatidylethanolamine (PE) and phospha-
tidylserine (PS) aminophospholipids as well as phosphati-
dylinositol (PI) phospholipid are primarily located in the
intracellular membrane [19]. Two ATP-dependent trans-
locase enzymes (i.e. cholinophospholipid-specific translo-
case or floppase, and aminophospholipid-specific
translocase or flippase) and a Mg
2+-ATPase (i.e. amino-
phospholipid translocase) maintain the aminophospholi-
pids in the inner leaflet of the membrane bilayer. PE and
PS are externalised to the outer leaflet of the cell mem-
brane after inactivation of aminophospholipid translocase
or flippase and activation of scramblase, another Ca
2+-
dependent ATP-independent enzyme [19,20].
Phospholipid targets
Phospholipids are composed of a phosphatidyl tail
including a free fatty acid, glycerol and phosphate [21].
In the phospholipid polar head, choline, serine, ethano-
lamine and inositol bind to the phosphatidyl non-polar
tail. Sphingomyelin is the only one cell membrane phos-
pholipid not derived from a glycerol but from an ami-
noalcohol sphingosine; SM is composed of a core
ceramide (i.e. sphingosine and free fatty acid tail) and
contains a polar head group composed of phosphocho-
line or phosphoethanolamine [22].
In preclinical and clinical research, phospholipids are
used as targets for molecular imaging with radiolabelled
probes as illustrated in Figure 3 [23,24].
PS target
PS is an aminophospholipid located in the inner leaflet
of the cell membrane. In pathophysiological conditions
including apoptosis, thrombosis and tumour vasculature,
PS is externalised from the inner leaflet to the outer
leaflet of the cell membrane [25]. In necrosis, PS is
exposed in the inner leaflet of damaged cells. For
SPECT-CT and PET-CT imaging, radiolabelled probes
have been designed to target exposed PS with or with-
out the breakdown of cell membrane asymmetry.
Annexin V, a 36-kDa serum protein first isolated from
human placenta, has been radiolabelled with
99mTc,
111In,
67Ga,
123I,
124I,
11C,
64Cu,
68Ga,
94mTc and
18F for imaging
of apoptosis or necrosis, and thrombosis [26-29]. Annexin
V binds specifically to PS in presence of Ca
2+ ions. Sponta-
neous and induced apoptotic changes may be assessed
qualitatively and quantitatively with radiolabelled annexin
V-targeted to PS [30,31]. In preclinical research,
99mTc-
HYNIC-annexin V imaging has been used to evaluate car-
diovascular models (e.g. heart transplant rejection, myo-
carditis and mural thrombus), oncology models (e.g.
cyclophosphamide induced intramedullary and splenic
apoptosis in lymphoma), neurology models (e.g. neonatal
brain ischemia), inflammatory/infectious models (e.g. ful-
minant hepatitis, subacute and acute infection) and
immune models (e.g. rheumatoid arthritis treated by corti-
costeroids). In clinical research,
99mTc-HYNIC-annexin V
imaging using a recombinant human form of annexin V
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plant rejection, atherosclerosis, ischemic pre-conditioning
and chemotherapy/radiation therapy-induced apoptosis in
head and neck cancers, lymphomas, lung cancers, breast
cancers, leukaemia and soft tissue sarcomas.
99mTc-
HYNIC-annexin V imaging has also been used in patients
with dementia and stroke, and in patients with rheumatoid
arthritis and Crohn’s disease for evaluation of early apop-
totic response to Infliximab
® therapy (i.e. anti-TNFa
monoclonal antibody) [24,26]. Figures 4 and 5 illustrate PS
targeting
99mTc-HYNIC-annexin V molecular imaging
probe in a patient with a non-small cell lung cancer
(NSCLC). PS targeting
99mTc-annexin V-128 with an N-
terminal site specific for endogenous binding of techne-
tium-99m has been designed in order to improve the sen-
sitivity of detection of apoptosis or necrosis (i.e. twofold
higher than that of
99mTc-HYNIC-annexin V) [32].
>C2A domain of synaptotagmin I (C2A) is a 12-kDa
protein predominantly located within the synaptic vesi-
cles binding to PS. It has been fused with glutathione-s-
transferase (GST) and radiolabelled with
99mTc for ima-
ging of apoptosis or necrosis [33]. In a rat and pig
model of acute myocardial infarction, increased
99mTc-
C2A-GST uptake was seen in the myocardial infarct
area at risk, and was associated with wall dysfunction
[34-36]. In a mouse model of NSCLC, increased
99mTc-
C2A-GST tumour uptake was noted after paclitaxel che-
motherapy-induced apoptosis [37]. Also, C2A-GST has
been easily labelled with
18F for early imaging of apopto-
sis after chemotherapy [38]. In a rabbit model of lung
cancer, increased
18F-C2A-GST tumour uptake was
detected 72 h after paclitaxel chemotherapy with
increased apoptotic index and caspase-3 activity.
Recently, the C2A domain of synaptotagmin I has been
labelled with a [
99mTc(CO)3
+] core by using an efficient
C-terminal site-specific radiolabelling method for the
imaging of cell death [39].
PS is not exposed in normal endothelium, but
increased exposure of PS is seen on the tumour
endothelium vasculature [40,41]. Bavituximab,ac h i -
meric monoclonal antibody (MW = 145.3 kDa) binding
to the beta-2 glycoprotein I domain of PS, has been
radiolabelled with the b + emitter arsenicum-74 (
74As,
T1/2 = 17.8 days) for tumour vasculature PET imaging,
and with the b-,g emitter
77As (T1/2 =3 8 . 8h )f o r
SPECT imaging and potential tumour vasculature
Figure 1 Phospholipid bilayer composed of hydrophobic non-polar tails and hydrophilic polar heads. Liposomes are artificial
phospholipid vesicles encapsulating materials either in an aqueous phase or in a lipid phase.
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74As-bavituxi-
mab uptake was seen in a rat model of prostate cancer
with the highest tumour-to-background activity ratio at
72 h post-i.v injection (at 72 h p.i., tumour-to-liver ratio
= 22, and tumour-to-muscle ratio = 470). Using autora-
diography and immunohistochemical studies,
74As-bavi-
tuximab was found to specifically bind to the tumour
endothelium vasculature. Bavituximab radiolabelled with
77As or
76As (b-, T1/2 = 26.3 h) may be used for dosime-
try and immunotherapy.
Hypericin, a non-porphyrin necrosis agent (MW = 504
Da) extracted from St John’s wort, has been labelled with
64Cu (b+, T1/2 = 12.7 h) for PET imaging of necrosis. In a
female mouse model of BT474 breast xenograft tumour,
64Cu-bis-DOTA-hypericin demonstrated increased uptake
at 24 h post-i.v. injection in necrotic injured tissues treated
with near infrared photothermal ablation therapy. PET
distribution also showed higher uptake in the liver and the
kidneys. Bis-DOTA-hypericin had a selective binding affi-
nity for PS and PE phospholipids [45]. In necrosis, PS and
PE are exposed to
64Cu-labelled hypericin probe in the
inner leaflet of damaged cell membrane. Hypericin deriva-
tives are efficient and yield reproducible results when
radiolabelled with
123I( i . e .m o n o -
123I-iodohypericin and
mono-
123I-iodohypericin monocarboxylic acid). They have
been also used in preclinical models of liver necrosis and
myocardial infarction as well as in clinical correlates of
these pathophysiologic states [46,47]. In a preclinical rat
model of liver rhabdomyosarcoma,
131I-labelled hypericin
was successfully used in theragnostics with a vascular dis-
rupting agent (i.e. combretastatin A4 phosphate or CA4P);
high radiolabelling efficiency was noted with minimum
deiodination.
131I-hypericin uptake colocalised tumour
necrosis within 24 h post-i.v. injection on co-registered
planar g scintigraphy with CT, MRI, histology and autora-
diography [48]. Hypericin has also been labelled with
99mTc (i.e.
99mTc-hypericin or
99mTc-mercaptoacetyldigly-
cyl-1,5-diaminopentylene hypericin-carboxamide) for
visualisation of necrotic tissues in rats with reperfused
liver infarct [49].
99mTc-hypericin, however, was found to
be not suitable for imaging of necrosis compared to
123I-
hypericin derivatives [50]. Although the mechanism of tar-
get uptake is unknown, it may be hypothesised that the PS
and PE phospholipid targets are involved for
123I-,
131I-
and
99mTc-labelled hypericin derivatives, but this is still to
be definitely proven.
Figure 2 Asymmetry of phospholipid distribution. Phosphatidylcholine (PC) and sphyngomyelin (SM) cholinophospholipids are primarily
located in the external leaflet of the cell membrane (ECM). Phosphatidylserine (PS) and phosphatidylethanolamine (PE) aminophospholipids as
well as phosphatidylinositol (PI) phospholipid are primarily located in the internal leaflet of the cell membrane (ICM). In mammalians, the
asymmetry of phospholipid distribution is maintained by the flip/flop movement of phospholipids. PS and PE are maintained to the inner leaflet
of the membrane bilayer by the Mg
2+-ATPase (i.e. aminophospholipid translocase), and the ATP-dependent aminophospholipid-specific flippase
and cholinophospholipid-specific floppase (i.e. multidrug resistance proteins). In pathophysiological conditions, PS and PE are shuttled to the
outer leaflet after inactivation of the aminophospholipid translocase or flippase, and activation of the Ca
2+-dependent ATP-independent
scramblase.
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epithelium, epididymal epithelium, vascular cells and
activated macrophages, has been shown to bind in a
Ca2+-independent manner and specifically to the C2
domain of PS [51-53]. In vitro, FITC-labelled bovine lac-
tadherin has been used for early detection of apoptosis
in leukaemia cell lines treated by etoposide, and also in
HeLa cervical cancer lines treated by staurosporine
[54,55]. HYNIC-lactadherin has also been successfully
labelled with
99mTc (i.e.
99mTc-HYNIC-lactadherin). In
vivo,i nam o u s em o d e l ,
99mTc-HYNIC-lactadherin had
a lower uptake in the kidneys compared to
99mTc-
HYNIC annexin V. However, this new PS-targeting
probe had a higher uptake in the liver, which is a disad-
vantage for imaging of liver and myocardial apoptosis
[56].
PSBP-6 or PS-binding peptide-6, a synthetic 14 amino
acid sequence (MW = 1.623 kDa; Kd = 100 nM) where
Gln is replaced by Ala screened through a peptide
library, showed the highest relative binding affinity and
stability; a single amino acid chelator (SAAC) was intro-
duced at the N-terminus position of PSBP-6 to form a
stable complex with
99mTc (i.e. SAAC-
99mTc-PSBP-6),
and to improve the labelling efficiency. Unlike annexin
V, SAAC-PSBP-6 binding to PS is Ca
2+ independent
[57]. In DLD1 human colon carcinoma cells pretreated
with increased TRAIL doses and also in murine
melanoma B16/F10 cells treated with poly(L-glutamic
acid) paclitaxel (PG-TXL), SAAC-(
99mTc)-PSBP-6
showed selective binding to apoptotic cells in vitro;c o n -
firmation was obtained with TUNEL staining and auto-
radiography. In treated and untreated nude mice,
biodistribution data showed increased SAAC-(
99mTc)-
PSBP-6 uptake in the liver and the kidney in vivo.P r e -
clinical studies are required to assess the sensitivity and
specificity of this new PS binding molecular imaging
probe. Table 1 summarises radiolabelled PS-based mole-
cular imaging probes.
PC target
Choline is a main component of biomembranes targeted
by the choline kinase enzyme, and is phosphorylated to
intracellular phosphocholine and extracellular phospha-
tidylcholine [58]. Choline has been labelled with
11C (i.e.
11C-choline) and more recently with
18F( i . e .
18F-fluoro-
choline) for PET-CT imaging [59,60]. With a longer
physical half-life,
18F-fluorocholine (
18F-FCH;
18F, T1/2 =
109 min) is more suitable than
11C-choline (
11C, T1/2 =
20 min) for PET-CT imaging. In human subjects,
18F-
FCH showed a fast blood pool clearance with a peak ≤
5 min post-i.v. injection, a fast tissue uptake and a pre-
dominantly renal excretion. Additionally,
18F-FCH bio-
distribution changes very slowly later than 10 min after
i.v. injection [61].
Figure 3 Phospholipid targets are composed of a phosphatidyl tail including free fatty acid, glycerol, and phosphate.I nt h e
phospholipid polar head, choline, serine, ethanolamine, and inositol bind to the phosphatidyl non-polar tail. Sphingomyelin is the only one cell
membrane phospholipid not derived from a glycerol but from an aminoalcohol sphingosine; SM is composed of a core ceramide (i.e.
sphingosine and free fatty acid tail) and contains a polar head group composed of phosphocholine or phosphoethanolamine.
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18F-FCH) and
11C-choline are
incorporated into the membrane phospholipids, and are
predominantly used for prostate cancer imaging and
brain tumour imaging [62,63]. In prostate cancer
patients,
18F-FCH is a promising tracer for detection of
primary prostate cancer, staging of lymph node and bone
metastases, and detection of recurrence after definitive
therapy [62-64]. In brain tumours, this agent may be use-
ful to detect glioblastoma multiforme, to distinguish
high-grade gliomas with a characteristic peri-tumoural
uptake from metastases and benign lesions, to guide a
stereotactic biopsy, and also to differentiate post-radia-
tion necrosis from recurrence [65-68]. Also,
11C-choline
and
18F-FCH have been used for hepatocellular carci-
noma (HCC) imaging [69-71]. In a woodchuck model,
11C-choline sensitivity for detection of well-differentiated
HCCs was higher than that of
18F-FDG, and in 12
patients with moderately differentiated HCCs, the
11C-
choline detection rate was better than that of
18F-FDG.
18F-FCH imaging has also successfully been performed
for detection of well-differentiated HCC in patients with
liver nodules or cirrhosis or chronic liver disease, and for
detection of recurrences from HCC [72,73].
Under normal glucose conditions, acetate free fatty
acid is metabolised into acetyl-CoA by acetyl-CoA
synthetase in both the cytosol and mitochondria for
synthesis of cholesterol and fatty acids [74]. In tumours,
acetate is metabolised into fatty acids by fatty acid
synthetase, which is overexpressed in cancer cells [75].
Acetate is mainly incorporated in the PC microdomains
that play a major role for growth and metastasis [76].
Acetoacetate ketone body is metabolised to acetoacetyl-
CoA and to acetyl-CoA, and then incorporated into the
metabolic pathway for lipid synthesis [77]. Like acetate,
acetoacetate could be incorporated into the PC mem-
brane. Acetate and acetoacetate have been labelled with
Figure 4 PS-annexin V imaging (North American Scientific 2020 - Phase II-III - Clinical Trial - Antwerp 2003). A patient with a left para-
hilar NSCLC (large black arrow) who presented with a bone metastasis in the right upper humerus (fine black arrow) on bone scan and
18FDG
PET.
99mTc-HYNIC-annexin V imaging showed tracer uptake in the primary tumour (large white arrow) and the bone metastasis (fine white
arrow) as soon as 24 h after the first course of chemotherapy. i.v., intravenous injection (dashed arrow).
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Page 6 of 14Figure 5 PS-annexin V imaging (North American Scientific 2020 - Phase II-III Clinical Trial - Antwerp 2003). A patient with a left para-hilar
NSCLC on pre-chemotherapy CT (upper right: simple white arrow) who presented with
99mTc-HYNIC-annexin V uptake post-chemotherapy in the
primary lung tumour (upper left: simple white arrow) and the right upper humerus bone metastasis (upper left: yellow arrow). After the first
course of chemotherapy, diagnostic CTs showed a decrease in the primary lung tumour greatest diameter, which was consistent with an
apoptotic tumour response to chemotherapy (lower left and lower right: simple white arrows). Upper left (A): post-chemotherapy
99mTc-HYNIC-
annexin V scan; upper right (B) and lower left (C): pre-chemotherapy diagnostic CTs; lower right (D): post-chemotherapy diagnostic CT.
Table 1 Phosphatidylserine-based radiolabelled molecular imaging probes
Molecular
target
Molecular probes AA MW
(kDa)
Affinity
(M)
Biological functions Isotopes Imaging
techniques
PS
a annexin V 319 36 10
-9 apoptosis, necrosis,
thrombosis
99mTc,
123I,
111In,
67Ga,
18F,
68Ga,
124I,
64Cu,
94mTc
SPECT(CT), PET
(CT)
PS C2A domain of
synaptotagmin I
128 12 10
-9 apoptosis, necrosis
99mTc SPECT(CT)
18F PET(CT)
PS
b bavituximab chimeric
antibody
- 145.3 10
-9 tumour endothelium
vasculature imaging
74As
c PET(CT)
tumour endothelium
vasculature therapy
77As
d SPECT(CT)
PS hypericin - 0.504 - necrosis
99mTc,
123I,
131I
64Cu
e
SPECT(CT)
PET(CT)
PS lactadherin 364 47 - 50 10
-9 apoptosis
99mTc
f SPECT(CT)
PS PSBP-6 14 1.623 10
-9 apoptosis, necrosis
99mTc
g SPECT(CT)
a Various linkers have been used for the radiolabelling of annexin V [26]. HYNIC is the most used bifunctional chelating agent in preclinical and clinical research.
b b2 glycoprotein I domain of phosphatidylserine.
c7 4 As, b + emitter (T1/2 = 17.8 days).
d7 7 As, b- emitter (T1/2 = 1.6 days).
e Bis-DOTA has been used as a
bifunctional chelating agent for radiolabelling of hypericin.
f HYNIC has been used as a bifunctional chelating agent for radiolabelling of lactadherin.
g SAAC has
been used as a single amino acid chelator for radiolabelling of PSBP-6. AA, amino acids; MW, molecular weight; PET(CT), positron emission tomography
(computed tomography); PS, phosphatidylserine; PSBP-6, PS-binding peptide-6; SPECT(CT), single-photon emission computed tomography (computed
tomography).
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11C-acetate and
11C-acetoacetate) [74,77]. Acet-
ate has also been labelled with
18F( i . e .
18F-fluoroacetate)
[78].
11C-acetate has a rapid blood clearance with a high
accumulation in liver and myocardium. In normal phy-
siology,
18F-fluoroacetate is not a functional analogue of
11C-acetate;
18F-fluoroacetate has a longer blood half-life,
a rapid liver clearance and low myocardial uptake, exten-
sive excretion into bile and urine, and suffers from skele-
tal defluorination resulting in skeletal uptake of the
formed
18F-fluoride [79]. In preclinical and clinical
research,
11C-acetate PET imaging has been successfully
used for tumour imaging in cancers of the prostate, kid-
ney, pancreas, as well as gliomas, meningiomas and HCC
[80,81]. In preclinical research,
18F-fluoroacetate has
been used for imaging of gliosis in glioblastoma, stroke,
and ischemia-hypoxia associated with neuroinflammation
[82]. In CWR22 tumour-bearing male nu/nu mice,
18F-
fluoroacetate has been successfully used for prostate can-
cer imaging with a higher tumour-to-prostate activity
ratio compared to
11C-acetate at 30 min and 2 h post-i.v.
injection. In a patient with prostate cancer,
18F-fluoroace-
tate was also able to detect several but not all bone
metastases [83,84]. In other preclinical research models
of breast and prostate cancers,
11C-acetoacetate uptake
tended to be higher than that of
11C-acetate [85]. Assess-
ment of brain ketone metabolism in rats indicated a 7 to
8f o l di n c r e a s ei n
11C-acetoacetate under ketone dietary
treatment [86,87]. Table 2 summarises the radiolabelled
PC-based molecular imaging probes.
PE target
PE is primarily located in the inner leaflet of the mem-
brane bilayer [88]. Like PS, this major aminophospholi-
pid is externalised from the inner leaflet to the outer
leaflet of the cell membrane during apoptosis and
tumour vascular endothelium [89,90]. In necrosis, PE is
exposed in the inner leaflet of disintegrated cell
membrane.
Duramycin, a 2-kDa small protein produced by Strep-
tovercillium cinnamoneus, has been designed in order to
target PE for imaging of apoptosis or necrosis [91].
99mTc-HYNIC-duramycin has been successfully used in a
rat model of ischemia-reperfusion for imaging of myocar-
dial infarction cell death [92].
99mTc-duramycin is highly
stable in vivo, and has favourable pharmacokinetics for
early imaging of acute cardiac cell death at 10 min post-i.
v. injection with a fast blood clearance, a low liver uptake
and a high uptake in apoptotic and necrotic myocardium.
Figure 6 illustrates the PE targeting
99mTc-duramycin
molecular imaging probe in a rat model of myocardial
infarction with correlation by autoradiography.
In addition to this, radiolabelled ethanolamine (i.e.
ethanolamine labelled with
11Co r
18F) is a potential
new probe in oncology PET-CT imaging for assessment
of tumour proliferation [93].
14C-ethanolamine has
been used in a variety of tumour cell types (i.e. mela-
noma, prostate cancer, glioblastoma multiforme, diffuse
large B-cell lymphoma, colorectal adenocarcinoma).
14C-
ethanolamine is incorporated into PE and has a two- to
sevenfold significantly better uptake into tumour cell
types than
14C-choline. In an in vitro model of cultured
prostate cancer cells,
14C-ethanolamine and
14C-N, N’-
dimethyl-ethanolamine uptake was two- to fourfold
better in androgen-dependent and proliferating PC3
cells compared to androgen-independent and growth-
arrested LnCap cells.
Hypericin, a PE- and PS-targeting probe, has been
radiolabelled with
64Cu (i.e.
64Cu-bis-DOTA-hypericin),
123I (i.e. mono-
123I-iodohypericin and mono-
123I-iodohy-
pericin monocarboxylic acid),
131I( i . e .
131I-hypericin)
and
99mTc (i.e.
99mTc-hypericin) for imaging of necrosis
in preclinical and clinical research as described above in
the PS target section [45-50]. Table 3 summarises the
PE-based radiolabelled molecular probes.
PI target
PI phospholipid is located in the inner leaflet of the
membrane bilayer [94]. 1,2 Diacylglycerol (DAG) is
metabolised to intermediate phosphoinositide metabo-
lites (i.e. PA, PIP, PIP2, PIP3) including phosphatidylino-
sitol (PI) [95]. DAG activates the intracellular protein
kinase C (PKC) transduction signalling pathway, which
is involved in higher cortical functions (e.g. memory,
learning) and cardiac functions (e.g. hypertrophic
growth, ventricular remodelling).
Intact
11C-inositol (i.e. non-acetylated inositol) has
been suggested as a diagnostic agent in PET imaging for
evaluation of PI brain metabolism and its role as second
Table 2 Phosphatidylcholine-based radiolabelled molecular imaging probes
Molecular target Molecular probes Biological functions Isotopes Imaging techniques
PC choline choline metabolism
11C PET(CT)
PC fluorocholine choline metabolism
18F PET(CT)
PC acetate acetate metabolism
11C PET(CT)
PC fluoroacetate acetate metabolism
18F PET(CT)
PC acetoacetate acetoacetate metabolism
11C PET(CT)
PC, phosphatidylcholine; PET(CT), positron emission tomography (computed tomography).
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11C]-
butyryl-2-palmitoyl-rac-glycerol or
11C-DAG has been
designed as a PI-targeting probe in PET brain imaging
to visualise neuronal PI turnover [97,98].
11C-DAG
levels are low in the brain, and thus it may be appropri-
ately used to visualise PI metabolism in the central ner-
vous system. Dynamic PET imaging showed increased
11C-DAG uptake in the first 15 min with an equilibrium
at 16 min in pre-stimulation and post-stimulation con-
ditions, which is suggestive of a membrane trapping
mechanism.
11C-DAG uptake increased 20% to 30%
after arecoline stimulation (i.e. acetylcholine muscarinic
receptor stimulation), which suggests that
11C-DAG is a
tracer of the transduction signalling PI-mediated path-
way. In resting conditions,
11C-DAG uptake was
observed in the visual association area, and increased in
the whole brain and the occipital areas after arecoline
stimulation. In C6 glioma cells implanted in the rat
brain,
11C-DAG was rapidly incorporated in the PI turn-
over within 5 min post-i.v injection; in a patient with
astrocytoma grade III,
11C-DAG was gradually incorpo-
rated in the leading PI turnover and the PE-PC
Figure 6 PE-duramycin imaging.I n c r e a s e d
99mTc-Duramycin uptake is seen in acute myocardial infarction of the rat at 120 min post-i.v.
injection with excellent infarct-to-non infarct activity ratio (right). Autoradiography confirmed radioactivity uptake within the myocardial
infarction. No tracer uptake is seen in the healthy rat (left). B, bladder; K, kidney. Courtesy of Pr. Zhao M (Department of Biophysics, Medical
College of Wisconsin, Milwaukee, WI, USA). Previously published in the J Nucl Med 2008, 49(8):1345-52.
Table 3 Phosphatidylethanolamine-based radiolabelled molecular imaging probes
Molecular
target
Molecular probes AA MW
(kDa)
Affinity
(M)
Biological functions Isotopes Imaging
techniques
PE duramycin 19 2 10
-9 apoptosis
necrosis
99mTc
a SPECT(CT)
PE ethanolamine
N’N-dimethyl
ethanolamine
- - - ethanolamine metabolism (tumour
proliferation)
14C
b PET(CT)
PE
c hypericin - 0.504 - necrosis
123I,
131I
99mTc
SPECT(CT)
64Cu
d PET(CT)
a HYNIC has been used as a bifunctional chelating agent for the radiolabelling of duramycin.
b ethanolamine or N,N’-dimethylethanolamine labelled with
14Ci n
preclinical in vitro research may be labelled with
11Co r
18F for PET(CT) in vivo imaging.
c6 4 Cu-bis-DOTA-hypericin has a selective binding affinity for PS and PE
(ref.45); it may be hypothesised that
123I-,
131I- and
99mTc-labelled hypericin derivatives bind to PS and PE.
d bis-DOTA has been used as a bifunctional chelating
agent for the radiolabelling of hypericin. AA, amino acids; MW, molecular weight; PE, phosphatidylethanolamine; PET(CT), positron emission tomography
(computed tomography); SPECT(CT), single-photon emission computed tomography (computed tomography).
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post-iv. injection [99]. In patients with Alzheimer’sd i s -
ease and ischemic stroke,
11C-DAG evaluated the PI
cortical function and neural viability, respectively. In
eight patients with Alzheimer’sd i s e a s e ,
18F-FDG PET
imaging showed bilateral hypometabolism in the par-
ieto-temporal association areas, while
11C-DAG imaging
showed spotty uptake in the frontal lobes of the brain
suggestive of compensatory plastic process in non-
damaged neural circuits to degenerative cognitive
impairment [100]. In five patients with cerebral infarc-
tion, dynamic PET brain imaging showed decreased
11C-DAG uptake in comparison to normal cortex [101].
11C-DAG pharmacokinetics demonstrated rapid
decrease in the plasma with a peak at 40 s post-i.v.
injection, and gradual increase in the brain to reach a
p l a t e a ua t1 5t o2 0m i np o s t - i . v .i n j e c t i o n .R e f l e c t i n g
neural signal transduction activity, the incorporation
constant of
11C-DAG (k*DAG) was best correlated with
the cerebral metabolic rate of O2 (CMRO2). Maintained
PI metabolism suggested preservation of neural viability
in the peri-infarct area of the ischemic stroke. Patients
with subacute local brain injury, either ischemic stroke
or brain tumour, also exhibited
11C-DAG spots located
in the associative areas distant from the lesion between
2 weeks and 1 month after injury; one of the possible
features of neural recovery in the intact brain related to
PI metabolism in PET imaging [102].
In a rat model,
11C-DAG has also been used for asses-
sing the myocardial PI turnover [103].
11C-DAG incor-
poration into intermediate PI metabolites was seen both in
the infarcted and the non-infarcted myocardium at 7 days
after myocardial infarction. Furthermore,
11C-DAG has
been used to evaluate the PI-mediated angiotensin II sig-
nalling pathway. In a rat model of infarcted myocardium,
11C-DAG assessed the effect of angiotensin-converting
enzyme inhibitor (i.e. captropril) on activated PI metabo-
lism in order to reduce left ventricular remodelling in the
early phase of myocardial infarction [104]. After 3 weeks
of treatment with captropril, a significant decrease of
11C-DAG uptake was seen in the infarcted myocardium
compared to the non-infarcted myocardium, while
201Tl
imaging showed decreased uptake in the infarcted myocar-
dium with and without captopril treatment. In patients
with myocardial infarction,
11C-DAG has been used to
evaluate the PI myocardial turnover and the left
ventricular remodelling [105]. In 13 patients with myocar-
dial infarction,
11C-DAG was significantly correlated with
the myocardium-to-left atrium chamber ratio, the left ven-
tricle ejection fraction, and the brain natriuretic peptide
concentration. Significant increase of
11C-DAG uptake
was seen in the remote viable region of myocardial infarc-
tion patients compared to healthy subjects. DAG has also
been labelled with
18F to trace the PI metabolism into the
ventricular myocardium [106].
18F has a longer half-life,
and
18F-DAG may be more useful for clinical routine than
11C-DAG. In the rat myocardium, 3, 5, 10, and 30 min
after i.v. injection of 1-[4-[18F]fluorobutyryl]-2-palmitoyl-
glycerol (C4, C16),
18F-DAG reflected the myocardium PI
metabolism in the early phase (3 to 5 min); in the late
phase (≥ 30 min) after i.v. injection,
18F-DAG may also
reflect the PE metabolism. Quantification of PI metabo-
lism requires further optimization with a
18F-radiolabelled
DAG compound closer to the PI metabolism than
18F-
DAG (C4, C16) [106]. Table 4 summarises the PI-based
radiolabelled molecular imaging probes.
SM target
SM is a cholinophospholipid located in the outer leaflet
of the membrane bilayer [19]. Liposomes composed of
SM have been experimentally used for tumour imaging.
In a mouse tumour model, serum stable SM liposomes-
encapsulating
67Ga prepared in a lipid phase with cho-
lesterol (SM/cholesterol molar ratio, 2:1) enhanced
blood circulation and increased
67Ga delivery to the
tumour [107]. Tumour-to-blood activity ratio (T/B)a n d
tumour index (TI = T/B × percentage dose per gram)
were higher at 24, 48 and 72 h post-injection.
Neutral SM liposomes with encapsulated
67Ga in an
aqueous phase offer better radiolabelling properties and
67Ga accumulation for tumour imaging [108]. Table 5
summarises the SM-based radiolabelled molecular ima-
ging probes.
Conclusion
In nuclear medicine, the transbilayer phospholipid tar-
gets are used in preclinical and clinical research for
SPECT-CT and PET-CT molecular imaging with radi-
olabelled probes to assess key biological functions:
1. the PS target allows the visualisation, characterisa-
tion, and measurement of apoptosis or necrosis, and
thrombosis with radiolabelled annexin V and the
99mTc
Table 4 Phosphatidylinositol-based radiolabelled molecular imaging probes
Molecular target Molecular probes Biological functions Isotopes Imaging techniques
PI inositol
a PI brain metabolism
11C PET(CT)
PI DAG PI myocardial turnover
11C,
18F PET(CT)
PI DAG PI neuronal turnover
11C PET(CT)
a intact inositol: no acetylated analogues. DAG, diacylglycerol; PET(CT), positron emission tomography (computed tomography); PI, phosphatidylinositol.
Belhocine and Prato EJNMMI Research 2011, 1:17
http://www.ejnmmires.com/content/1/1/17
Page 10 of 14or
18F-labelled C2A domain of synaptotagmin I and the
99mTc-labelled HYNIC-lactadherin;
99mTc-labelled syn-
thetic PSBP-6-SAAC probe has been designed for mole-
cular imaging of cell death. PS targeting probes may
allow imaging of tumour endothelium vasculature with
74As-bavituximab.
77/76As-bavituximab may also serve for
b- radioimmunotherapy of tumours with PS exposed
endothelium tumour vasculature.
2. the PE target allows imaging of apoptosis or necro-
sis with
99mTc-HYNIC-duramycin. It may also allow
tumour imaging with radiolabelled ethanolamine and N,
N’ dimethylethanolamine.
3. the PS and PE targets allow imaging of necrosis
with the radiolabelled
64Cu-bis-DOTA hypericin.
4. the PC target allows assessment of choline metabo-
lism with
11C-choline or
18F-fluorocholine, and also the
evaluation of the acetate and acetoacetate metabolism
with
11C-acetate or
18F-fluoroacetate and
11C-acetoacetate.
5. the PI target allows evaluation of the neuronal and
myocardial PI turnover with
11Co r
18F-labelled DAG,
and also with
11C-inositol.
6. the SM target may be used with liposomes encapsu-
lating
67Ga for imaging purposes.
7. Translation of preclinical research to clinical
research will be necessary to optimally assess the phar-
macokinetics of radiolabelled probes for molecular ima-
ging of transbilayer phospholipids.
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